Overview of PNH
Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired disease, characterised by intravascular haemolysis, thrombosis...
MoreWho Should be Tested?
The International PNH Interest group (I-PIG) and the International Clinical Cytometry Society (ICCS) have advised the fo...
MoreThe National PNH Service
The National PNH Service was established in April 2009 following a successful application to the then National Commissio...
MoreReferral Information
Who to Refer? All patients who have PNH cells detected in their blood should be referred to the PNH Service. Patients se...
MoreEculizumab Administration Guidelines
Eculizumab is given weekly for the initial 5 weeks and then every 14 days from week 5 onwards. The dose is as follows: I...
MoreIndications for Treatment with Eculizumab
Patients fulfilling any of the following categories: Thrombosis related to PNH Complications associated with haemolysis:...
MoreMeningococcal Infection and Eculizumab/Complement Inhibitors
Eculizumab and complement inhibitors inhibit the formation of terminal complement, which has a dramatic effect in preven...
MorePNH Registry
Information for Patients The PNH Registry is an international research database that collects anonymised data on patient...
More